Last reviewed · How we verify
NCT03715231
NIDEK Gonioscope GS-1 for Glaucoma
NA trial testing NIDEK Gonioscope GS-1 in Glaucoma in 24 participants. Completed in 26 May 2021.
26 May 2021
Quick facts
| Lead sponsor | NYU Langone Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 24 |
| Start date | 12 June 2019 |
| Primary completion | 26 May 2021 |
| Estimated completion | 26 May 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- NIDEK Gonioscope GS-1
- Standard Digital Gonioscopic Images
Conditions studied
- Glaucoma — all drugs for Glaucoma →
Sponsor
NYU Langone Health — full company profile →
Who can join
Adults 18 to 100, any sex, with Glaucoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Gonioscope GS-1 is an ophthalmic camera with gonioscopic prism that is intended to capture, display and store images of the anterior chamber angle and its peripheral part. This study evaluates the efficiency of Gonioscope GS-1 in glaucoma patients.With the captured images, the glaucoma diagnosis and post-operative observation are enabled.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Automated 360-degree goniophotography with the NIDEK Gonioscope GS-1 for glaucoma.
Madu CT, Phelps T, Schuman JS, Zambrano R, et al · · 2023 · cited 2× · PMID 36881575 · DOI 10.1371/journal.pone.0270941
Verify or expand the search:
- PubMed search for NCT03715231
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glaucoma
Currently open trials in the same condition.
- NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
- NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
- NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
- NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
- NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting
Other NYU Langone Health trials
Trials by the same sponsor.
- NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
- NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
- NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
- NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
- NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03715231 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
- Last refreshed: 30 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03715231.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing